Q2 2024 EPS Estimates for Sarepta Therapeutics, Inc. Reduced by Leerink Partnrs (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Leerink Partnrs dropped their Q2 2024 EPS estimates for Sarepta Therapeutics in a report issued on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($0.12) per share for the quarter, down from their previous estimate of $0.19. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.23 per share.

Other equities analysts have also issued reports about the company. Royal Bank of Canada raised their price target on Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Mizuho upped their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Barclays boosted their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Finally, UBS Group lifted their price target on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $160.60.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $135.04 on Monday. The firm has a market cap of $12.76 billion, a price-to-earnings ratio of 1,227.64 and a beta of 0.95. The company has a 50-day simple moving average of $125.63 and a two-hundred day simple moving average of $110.74. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company’s revenue was up 63.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.44) EPS.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently made changes to their positions in the company. Capital International Investors boosted its holdings in shares of Sarepta Therapeutics by 160.0% in the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares during the last quarter. Norges Bank bought a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at $80,697,000. Bank of Nova Scotia purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $50,990,000. Avoro Capital Advisors LLC raised its holdings in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares during the period. Finally, Mizuho Markets Americas LLC purchased a new position in Sarepta Therapeutics during the third quarter valued at $29,813,000. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the transaction, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. Insiders have sold a total of 25,731 shares of company stock worth $3,248,319 in the last quarter. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.